Sarepta股價下跌，因Elevidys未獲歐盟監管機構支持

英為財情

2025/07/25

Investing.com - Sarepta Therapeutics Inc. (NASDAQ:SRPT)股價周五下跌13%，此前歐洲監管機構建議不批准該公司用於治療杜氏肌營養不良症的基因療法Elevidys。歐洲藥品管理局的藥物諮詢委員會(CHMP)周五宣佈，拒絕批准Elevidys用於治療3至7歲能夠行走的兒童。這種療法在美國以外由羅氏控股(Roche Holding AG) (...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2554616117"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2554616117\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2554616117?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-25 19:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554616117","market":"sh","top_or_hot":-1,"title":"Sarepta股價下跌，因Elevidys未獲歐盟監管機構支持","media":"英為財情","content":"<div>\n<p>Investing.com -  Sarepta  Therapeutics Inc. (NASDAQ:SRPT)股價周五下跌13%，此前歐洲監管機構建議不批准該公司用於治療杜氏肌營養不良症的基因療法Elevidys。\n歐洲藥品管理局的藥物諮詢委員會(CHMP)周五宣佈，拒絕批准Elevidys用於治療3至7歲能夠行走的兒童。這種療法在美國以外由羅氏控股(Roche Holding AG) (...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-2903281\">網頁鏈接</a>\n\n</div>\n","source":"investing_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sarepta股價下跌，因Elevidys未獲歐盟監管機構支持</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSarepta股價下跌，因Elevidys未獲歐盟監管機構支持\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">英為財情</strong><span class=\"h-time small\">2025-07-25 19:08</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Investing.com -  Sarepta  Therapeutics Inc. (NASDAQ:SRPT)股價周五下跌13%，此前歐洲監管機構建議不批准該公司用於治療杜氏肌營養不良症的基因療法Elevidys。\n歐洲藥品管理局的藥物諮詢委員會(CHMP)周五宣佈，拒絕批准Elevidys用於治療3至7歲能夠行走的兒童。這種療法在美國以外由羅氏控股(Roche Holding AG) (...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-2903281\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://cn.investing.com/news/stock-market-news/article-2903281\">英為財情</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0002141913.USD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","start_time":0,"source_url":"https://cn.investing.com/news/stock-market-news/article-2903281","article_id":"2554616117","we_media_id":null,"thumbnails":[],"rights":{"source":"investing_news","url":"https://cn.investing.com/news/stock-market-news/article-2903281","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2554616117","pubTimestamp":1753441680,"columns":[],"sourceInfo":{"source_id":"investing_news","name":"英为财情新闻"},"weMediaInfo":null,"summary":"Investing.com -  Sarepta  Therapeutics Inc. 股價周五下跌13%，此前歐洲監管機構建議不批准該公司用於治療杜氏肌營養不良症的基因療法Elevidys。歐洲藥品管理局的藥物諮詢委員會周五宣佈，拒絕批准Elevidys用於治療3至7歲能夠行走的兒童。這一挫折緊隨美國食品藥品監督管理局最近要求暫停在美國使用Elevidys之後。Sarepta本周早些時候已宣佈暫時停止在美國的出貨。在美國和歐洲市場的雙重監管挫折，對Sarepta的Elevidys商業化戰略構成了重大挑戰，該產品此前被定位為這種衰弱性疾病的突破性治療選擇。","collect":0,"end_time":0,"defaultTopTitle":"investing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SRPT":"Sarepta Therapeutics","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4585":"ETF&股票定投概念","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4087":"商业印刷","BK4139":"生物科技","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","CHMP":"冠军工业"},"translate_title":"Sarepta shares fall as Elevidys doesn't get support from EU regulators","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRPT":1,"CHMP":1},"content_text":"Investing.com -  Sarepta  Therapeutics Inc. (NASDAQ:SRPT)股價周五下跌13%，此前歐洲監管機構建議不批准該公司用於治療杜氏肌營養不良症的基因療法Elevidys。\n歐洲藥品管理局的藥物諮詢委員會(CHMP)周五宣佈，拒絕批准Elevidys用於治療3至7歲能夠行走的兒童。這種療法在美國以外由羅氏控股(Roche Holding AG) (SIX:ROG)負責銷售，此前正尋求獲批用於治療這種導致肌肉進行性衰弱的罕見遺傳性疾病。\n這一挫折緊隨美國食品藥品監督管理局(FDA)最近要求暫停在美國使用Elevidys之後。Sarepta本周早些時候已宣佈暫時停止在美國的出貨。\n羅氏也已在參考FDA批准的司法管轄區暫停出貨，進一步限制了該療法的市場覆蓋範圍。這家瑞士製藥巨頭在與Sarepta合作後，負責在美國以外市場商業化這一治療方案。\n杜氏肌營養不良症是一種罕見的遺傳性疾病，主要影響男孩，導致肌肉進行性退化。這種疾病最終是致命的，患者通常會經歷嚴重的行動障礙，壽命也會縮短。\n在美國和歐洲市場的雙重監管挫折，對Sarepta的Elevidys商業化戰略構成了重大挑戰，該產品此前被定位為這種衰弱性疾病的突破性治療選擇。\n本文由人工智能協助翻譯。更多信息，請參見我們的使用條款。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}